Phase 3 Clinical Trials With Primary Completion Dates in August 2024
This is a list of Phase 3 trials with primary completion dates in August 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
---|---|---|---|---|---|
CASBF | CanSino Biologics Inc. | 2024-08-01 | Phase 3 | NCT05951725 | A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) |
ITCI | Intra-Cellular Therapies, Inc. | 2024-08-01 | Phase 3 | NCT04959032 | Lumateperone for the Prevention of Relapse in Patients With Schizophrenia |
MBOT | Microbot Medical Inc. | 2024-08-01 | Phase 3 | NCT06141694 | Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv. |